CHMP recommends approval of 'improved Prograf' in Europe
This article was originally published in Scrip
Executive Summary
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Veloxis Pharmaceuticals' Envarsus (formerly LCP-Tacro) for the prevention of organ rejection in adult transplant patients in the European Union (EU).